scispace - formally typeset
J

Jun Ma

Researcher at Harbin Institute of Technology

Publications -  1523
Citations -  58397

Jun Ma is an academic researcher from Harbin Institute of Technology. The author has contributed to research in topics: Nasopharyngeal carcinoma & Medicine. The author has an hindex of 97, co-authored 1338 publications receiving 39643 citations. Previous affiliations of Jun Ma include Shenyang Aerospace University & University of Technology, Sydney.

Papers
More filters
Journal ArticleDOI

Interpreting the effects of natural organic matter on antimicrobial activity of Ag2S nanoparticles with soft particle theory.

TL;DR: NOM coating may physically alleviate the contact between NPs and E. coli cells and thus attenuate the extent of cell membrane damage caused by the NP-cell interaction, and provides a new perspective for quantitatively interpreting the influence of NOM on the environmental behaviors and risks of nanomaterials.
Journal ArticleDOI

Graphene platelets versus phosphorus compounds for elastomeric composites: flame retardancy, mechanical performance and mechanisms.

TL;DR: GnPs improved ignition time by 29% and fire performance index by 62%, being advantageous over APP, and bonded during combustion with those degraded, viscous EPDM macromolecules, forming a thick solid char layer which prevented the transport of heat and smoke.
Journal ArticleDOI

Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis

TL;DR: The treatment outcomes of the NACT + RT and CCRT groups were similar; however, C CRT led to higher rates of acute and late toxicities, and NACT-+-RT may be a better treatment strategy for ascending-type NPC.
Journal ArticleDOI

Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma

TL;DR: Ten-year outcomes confirmed that C CRT could improve the OS of stage II patients without adding late toxicities compared with conventional RT, and the survival benefits earned by CCRT mainly reflected in T2N1 population.